Atlas Trials

Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area

Clinical trial NCT03008122 · COMPLETED

Trial details

NCT number
NCT03008122
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Zika Virus Infection
Start date
2017-03-21
Primary completion
2021-08-10
Enrollment
91

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.